Baseline characteristics

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer · Source last updated 2017-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      1

   units

   Participants

groups

1. description

   Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

   id

   BG000

   title

   Alemtuzumab

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            47

            upper Limit

            47

            value

            47

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            0

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            1

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice